Vera Therapeutics Inc. (VERA) has released findings from its ORIGIN Phase 2b study on atacicept for immunoglobulin A nephropathy (IgAN), revealing stable kidney function over a long-term follow-up period of 96 weeks.
Commenting on the outcome, Jonathan Barratt, MD, PhD, FRCP, and Mayer Professor of Renal Medicine at the University of Leicester, stated: "The 96-week results from the ORIGIN Phase 2b study have shown ongoing significant reductions in Gd-IgA1, hematuria, and proteinuria, as assessed by UPCR, along with steady preservation of eGFR over the long term."
During the 96-week period, participants receiving atacicept experienced a 66% decrease in galactose-deficient IgA1 (Gd-IgA1), hematuria resolution in 75% of the participants, a 52% reduction in proteinuria, and an average annualized estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m²/year.
The company highlighted that the overall favorable safety profile of atacicept observed during the initial randomized phase persisted, with a 90% completion rate of the treatment.
Vera Therapeutics asserts that these findings bolster the potential of atacicept for long-term, comprehensive modification of IgAN and reinforce confidence in the progress of the pivotal Phase 3 ORIGIN 3 trial of atacicept for IgAN.
